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ABSTRACT
Objectives  To summarise existing evidence on a target 
oriented approach for rheumatoid arthritis (RA) treatment.
Methods  We conducted a systematic literature search 
including all clinical trials testing clinical, functional, 
or structural values of a targeted treatment approach. 
Our search covered Medline, Embase and Cochrane 
databases until December 2008 and also conference 
abstracts (2007, 2008).
Results  The primary search yielded 5881 citations; 
after the selection process, 76 papers underwent 
detailed review. Of these, only seven strategic clinical 
trials were extracted: four studies randomised patients 
to routine or targeted treatment, two compared two 
different randomised targets and one compared targeted 
treatment to a historical control group. Five trials dealt 
with early RA patients. All identiﬁ  ed studies showed 
signiﬁ  cantly better clinical outcomes of targeted 
approaches than routine approaches. Disability was 
reported in two studies with no difference between 
groups. Four studies compared radiographic outcomes, 
two showing signiﬁ  cant beneﬁ  t of the targeted approach.
Conclusion  Only few studies employed randomised 
controlled settings to test the value of treatment to 
a speciﬁ  c target. However, they provided unanimous 
evidence for beneﬁ  ts of targeted approaches. 
Nevertheless, more data on radiographic and functional 
outcomes and on patients with established RA are 
needed.
INTRODUCTION
Many new treatment options make unprecedented 
outcomes achievable in rheumatoid arthritis 
(RA).1 2 In parallel, insights on the importance of 
early effective therapy3 4 and implications of dis-
ease activity on function5 6 and joint damage6–8 led 
to paradigmatic changes in therapeutic approaches, 
such as frequent evaluations of disease activ-
ity to allow for timely changes of therapies.9–13 
Additionally, validated composite disease activity 
measures have made disease activity assessment 
easy.14 15 Nevertheless, heterogeneity of therapeu-
tic aims and patient expectations16 characterise 
daily practice of RA treatment.17 All this suggests a 
need to provide rheumatologists and patients with 
pertinent information on therapeutic targets and 
means to achieve them.18 19
Strict deﬁ   nitions of treatment targets intend 
to facilitate strategic acting in routine care and 
require physicians and patients to discuss and 
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adopt therapeutic changes within distinct time 
frames, ideally following therapeutic algorithms. 
This approach has been utilised in many diseases, 
like diabetes,20 21 hypertension22–24 or hyper-
lipidaemia.25 However, this policy needs to be evi-
dence based to the best possible extent.
Here we report on a systematic review of avail-
able evidence regarding the effects of treating RA 
strategically according to deﬁ  ned outcome targets.
METHODS
Shaping the systematic literature review
As a ﬁ  rst step, the international steering commit-
tee of the Treat-To-Target (T2T) project, compris-
ing a group of expert rheumatologists and a patient 
(MdW), designed a literature search that aimed at 
‘treating to target’-strategy trials in RA. The search 
was then performed by a project fellow (MS), a 
control search by a second fellow (RK) and by two 
mentors (DA, DvdH).
The following deﬁ   nitions were made: (1) strat-
egy trial – clinical trial of any RA drug treatment, 
in which a clear outcome target was the primary 
end point and therapeutic consequences of failing 
to reach the target were predeﬁ  ned; (2) targets – a 
target could be formulated by clinical, serological, 
patient-reported, functional, or radiographic vari-
ables; individual measures (eg, joint counts or acute 
phase reactants), composite scores (eg, disease activ-
ity score or simpliﬁ   ed disease activity index), or 
response criteria (eg, those deﬁ  ned by the American 
College of Rheumatology (ACR) or the European 
League Against Rheumatism) were considered alike; 
(3) outcomes – Clinical, functional, serological and/or 
radiographic changes, as deﬁ  ned in the respective 
trials, were compared between treatment groups.
Implementation of the systematic literature review
We searched Medline, Embase and Cochrane data-
bases from their inception until December 2008. 
Additionally, ACR and European League Against 
Rheumatism (EULAR) abstracts of 2007 and 2008 
were screened. The search was limited to humans, 
adults and the English language. Detailed inclusion 
and exclusion criteria and the list of search strings 
are shown in supplementary tables (tables S1 and 
S2). We did not exclude studies based on quality.
From the identiﬁ   ed strategy trials, data were 
extracted concerning deﬁ  nitions of targets and suc-
cess rates of applied strategies.
This paper is freely available 
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was not attained with 3-monthly routine care. A cluster ran-
domised trial by Fransen et al  28 compared the proportion of 
patients reaching LDA at the end of follow-up and the number 
of disease-modifying antirheumatic drug (DMARD) changes dur-
ing 24 weeks (co-primary end points) in outpatient centres using 
systematic, DAS28-steered treatment protocols with centres pro-
viding routine care. The treatment decision in the DAS28-driven 
group depended on a threshold of 3.2, indicating LDA. Finally, 
Symmons et al29 tested the effect of aggressive versus symptom-
atic therapy on physical outcome (Health Assessment Questionnaire 
(HAQ)) in established RA. Decisions for treatment adaption were 
driven by joint count- and C reactive protein (CRP) thresholds. 
Designs of these trials are depicted in ﬁ  gure 2; baseline character-
istics are tabulated in supplementary table S3.
Characteristics of the core trials, including treatment targets 
and visit intervals, as well as clinical, functional and radiographic 
outcomes are summarised in table 1 and will be detailed below.
Signiﬁ   cantly greater DAS reduction and higher likeliness 
to achieve remission following intensive disease manage-
ment was evident in all four trials. In TICORA,26 the primary 
end point, EULAR good response, as well as DAS remission 
were signiﬁ  cantly more frequent upon intensive than routine 
care. CAMERA27 showed signiﬁ  cant beneﬁ  ts of targeted treat-
ment regarding its primary end point, remission for 3 months. 
RESULTS
We retrieved 5881 citations for further evaluation (ﬁ  gure 1). Title 
and abstract screening according to our selection criteria (sup-
plementary table S1) left 76 papers for detailed review. Among 
those, 17 trials published in full and 2 abstracts addressed direct 
assessment of treating to target. By hand search of references, we 
identiﬁ  ed three additional papers; further, one full paper and one 
abstract were included based on expert opinion. This gave a total 
of 24 publications for this review (ﬁ  gure 1), of which only 7 were 
strategic trials: 4 trials randomised patients to routine or targeted 
treatment,26–29 two compared different randomised targets30 31 
and one compared targeted treatment to historical control.32
Randomised strategic trials comparing targeted 
versus routine care
Only four trials had randomised patients to a targeted treatment 
algorithm versus routine care. In Tight Control of Rheumatoid 
Arthritis (TICORA),26 treatment of early RA aimed at low dis-
ease activity (LDA) by Disease Activity Score (DAS), comparing 
DAS-driven treatment adaptations upon monthly assessments 
with 3-monthly routine care. Computer Assisted Management 
in Early Rheumatoid Arthritis (CAMERA)27 aimed at remission 
of early RA, comparing monthly treatment adaptation by com-
puterised decision if >20% (50%) reduction of several variables 
Figure 1  Flow chart of the systematic literature search. Illustrated are the results of the initial search and the selection process of abstract 
screening, full text review and hand search. AB, abstract; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; 
RA, rheumatoid arthritis.
Papers retrieved and selection process
5881
Medline
n=2083
12/2008
￿ Non-human (n=26)
￿ Non-fulltext (n=1116)
￿ Non-english (n=49)
> Title Abstract 
Screening: 892
￿ Duplicates (n=25)
No RA (n=3)
￿ Wrong treat (n=36)
￿ Wrong outcome (n=276)
￿ Irrelevant (n=47) 
￿ No trial (n=228)
￿ No strategy trial (n=243)
Embase
n=3215
12/2008
￿ Non-human (n=58)
￿ Non-full text (n=1854)
￿ Non-english (n=70)
> Title Abstract
Screening: 1233
￿ No RA (n=12)
￿ Wrong treat (n=70)
￿ Wrong outcome (n=416)
￿ Review of interest (n=1)
￿ Irrelevant (n=35)
￿ No trial (n=213)
￿ No strategy trial (n=461)
ACR & EULAR
2007+2008 n=185
Excluded: 183
￿ No treatment of 
interest (n=138)
￿ No outcome of 
interest (n=18)
￿ No strategic trial 
(n=26)
￿ Already published
paper (n=1)
Cochrane
n=398
12/2008
Excluded Title/AB:
￿ Non-human (n=1)
￿ Non-english (n=29)
￿ Wrong treat (n=28)
￿ Wrong outcome (n=82)
￿ No trial (n=7)
￿ No strategy trial (n=234)
Excluded, n=19
￿ Dose titration standard dose 
(n=3)
￿ Definition of suboptimal
response (n=1)
￿ Treating to target optional
extension (n=1)
￿ No strategy trial (n=14)
Excluded, n=23
￿ Duplicates medline (n=20)
￿ No strategy trial (n=3)
Excluded, n=17
￿ Duplicates  medline (n=17)
For detailed review
n=17
For detailed review
n=25
For detailed review
n=34
Included
n=15
Included
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Included
n=0
Included
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Handsearch
n=3
Expert opinion
n=2
76
24
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group aiming at DAS28 remission, the other at suppressing car-
tilage degradation as assessed by measuring urinary C-terminal 
cross-linking of type II collagen. Results did not differ signiﬁ  -
cantly between the two groups with similar overall remission 
rates in both arms (ﬁ  gure 2, table 1). However, as the authors 
concede, this was a very small pilot study. Similarly, Edmonds 
et al31 reported in abstract form on steering at normal CRP levels 
versus a joint count targeted approach. Their results suggested 
that targeting CRP provides better interference with radio-
graphic damage (table 1, ﬁ  gure 2).
Non-randomised cohort studies comparing 
two targeted strategies
Stenger  et al32 compared an aggressive treatment protocol 
that stipulated change of DMARD therapy if after 8 weeks 
CRP decrease was less than 50% in patients with a high risk 
of developing aggressive disease; the comparator arm on reg-
ular therapy was a retrospectively assessed group of high risk 
patients. After 2 years, the area under the curve for CRP was 
signiﬁ   cantly lower in the intensive treatment group than in 
the historic control. While no functional data were provided, 
Fransen  et al28 showed that both the proportion of patients 
reaching LDA and frequency of DMARD changes during fol-
low-up favoured a DAS28-driven DMARD strategy. Symmons 
et al29 found signiﬁ  cant differences in clinical outcomes in the 
evaluator global assessment, while other measures, including 
joint counts, erythrocyte sedimentation rate and patient global visual 
analogue scale, were not signiﬁ  cantly different.
Physical function was the primary outcome in the trial by 
Symmons et al29; the intensive group failed to show signiﬁ  cant 
differences compared to routine care regarding HAQ changes. 
Also CAMERA27 did not show signiﬁ  cant differences in func-
tional outcomes.
Grigor et al26 reported signiﬁ  cantly less progression of radio-
graphic changes26 in the intensive treatment group. In contrast, 
no signiﬁ   cant differences in annual radiographic progression 
were described in the CAMERA study.27 Two of the studies did 
not report radiographic data28 29 (table 1, ﬁ  gure 2).
Randomised strategic trials comparing two targeted strategies
van Tuyl et al30 presented a study protocol randomising early RA 
patients to different targeted and tight monitoring schedules: one 
Figure 2  Design of the seven core clinical trials. (A) TICORA study (Grigor et al 2004)26; (B) CAMERA study (Verstappen et al 2007)27; (C) Fransen 
et al 200528; (D) Symmons et al 200529; (E) Edmonds et al 2007 (abstract)31; (F) van Tuyl et al 200830; and (G) Stenger et al 1998.32 Intensive and 
routine treatment arms are displayed, red arrows mark the scheduled intervals for target assessment. Table 1 speciﬁ  es the targets of trials A–G. AZA, 
Azathioprine; CAMERA, Computer Assisted Management in Early Rheumatoid Arthritis; CRP, C reactive protein; DAS, Disease Activity Score; DMARD, 
disease-modifying antirheumatic drug; HCQ, hydroxychloroquine; IFX, ifosfamide; LDA, low disease activity; LEF, leﬂ  unomide; MTX, methotrexate; 
NSAID, non-steroidal anti-inﬂ  ammatory drug; sc, subcutaneous; SJC, swollen joint count; sod., sodium; SPZ, sulﬁ  npyrazone; TICORA, tight control of 
rheumatoid arthritis.
A TICORA26
Intensive
3 months (≠)
1 month
DAS<2.4 LDA
18 months
DMARD step up to trippletherapy; SPZ, MTX,
HCQ,steroids, LEF, sod. aurothiomalat 
if active synovitis, or„LOE“ortoxicity, 
DMARD switch of monotherapy, stepup;
steroids (≠)
Routine ‘Opinion of treating rheumatologist’
B CAMERA27
Response Criteria*
1 month
3 months (≠)
MTX dose adjustments s.c. application , add
of cyclosporine
Intensive
Routine
2 years 
MTX dose adjustments , s.c. application add
of cyclosporine(=)
SJC +‘opinion of treating rheumatologist’ 
F van Tuyl30
Intensive I
DAS28<3.2 LDA
40 weeks
week 8: DMARDs (COBRA treatment including 
MTX, SPZ, HCQ prednisolone),
week21: add IFX
week8: DMARDs,
week21: IFX (=)
Intensive II
8 weeks 13 weeks 13 weeks
8 weeks 13 weeks(=)
Cartilage degradation (≠)
G Stenger32 CRP decrease ? 50%*
2 years
‘Opinion of treating rheumatologist’
8 weeksafter MTX, SPZ, AZA
6 months after i.m. gold
DMARDs, stepup*, aggressive
Experimental
high risk
Control high risk NSAIDs only, DMARD monotherapy(≠)
Experimental 
low risk 11.4% NSAIDs only, DMARD monother. (≠) 
C Fransen28
Intensive
1 month
DAS28<3.2 LDA
24 weeks
DMARDs
DMARDs (=)
Routine ‘Opinion of treating rheumatologist’
2 months 3 months months
3 months (=) 1 month 2 months
D Symmons29 CRP below twice upper limit of normal
(+SJC,symptoms)* 
At least every4 months 
4 months(≠) 
DMARDs incl.Cyclosporin, Cyclophosphamide,
parenteral steroids (im, iv) Intensive
Routine
3 years 
NSAIDs, DMARDs, steroids(≠) symptomcontrol
CRP decrease≤50%  Targeted (G) Stenger
et al, 199832
‘opinion of treating rheumatologist’ Routine
DAS28≤3.2 LDA  Targeted I (F) van Tuyl 
et al, 200830
Cartilage degradation (CTX-II  ≤150in ELISA) Targeted II
SJC<3 Targeted II
CRP normal range Targeted I (E) Edmonds 
et al, 
(abstract) 
200731
‘symptom control’ Routine
suppressing clinical and laboratory evidence of joint inflammati on: SJC & TJC 
= 0, CRP less than twice the upper limit of the normal range.
Targeted (D) Symmons 
et al, 200529
‘opinion of treating rheumatologist’ Routine
DAS28≤3.2 LDA  Intensive (C) Fransen 
et al, 200528
SJC + ‘opinion of treating rheumatologist’ Routine
Response criteria: >20 % improvement compared to previous visit of SJC and 
2 out of 3: ESR, TJC, PGA
≤50% improvement compared to baseline of SJC and 2 out of 3: ESR, TJC,
PGA (inadequate response)
Targeted
(B) CAMERA 
study; 
Verstappen
et al, 200727
‘Opinion of treating rheumatologist’ ; synovitis, ‘lack of efficacy’ Routine
DAS<2.4 LDA Targeted (A) TICORA 
study; Grigor 
et al, 200425
Target Groups Trial
E Edmonds31
Intensive I
CRP normal range
2 years
Intensive II
1 month
SJC<3
1 month
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Table 1  Targets and visit intervals (left columns) and clinical, functional and structural outcomes (right columns) of core trials
Group
Treatment-decision driving 
target
Interval of 
controls N
Outcomes/ﬁ  nal treatment target p Values indicate differences of outcomes between 
the targeted (T) and the routine group (R)
(A) TICORA26
Targeted group (T) DAS<2.4 LDA 1 Month   55 Clinical outcome at 18 months
  EULAR good response (primary outcome): OR* 5.8 (2.4 to 13.9); 82% targeted (T) versus 
44% routine (R); p<0.0001
  EULAR remission: OR* 9.7 (3.9 to 23.9), 64% T versus 16% R; p<0.0001
  ACR70: OR* 11 (4.5 to 27), 71% T versus 18% R; p<0.0001 Functional outcome at 18 
months
  HAQ change: −0.97±0.8 T versus −0.47±0.9 R; p=0.0025 Radiographic outcome at 18 
months; median (IQR)
  Progression of erosion score: 0.5 (0–3.357) T versus 3 (0.5–8.5) R; p=0.002
  Change in TSS: 4.5 (1–9.875) T versus 8.5 (2.0–15.5) R; p=0.02
  Change in JSN: 3.25 (1.125–7.5) T versus 4.5 (1.5–9.0) R; p=0.331
Routine control 
group (R)
Opinion of treating 
rheumatologist
1 Month   55
(B) CAMERA27
Targeted group (T) Improvement of number of 
swollen joints: >20% 
compared to previous 
visit/50% compared to 
baseline
Improvement in 2 out of 
3 criteria: ESR, TJC, PGA 
>20% compared to 
previous visit
1 Month 151 Clinical outcome at 1 year† and at 2 years‡
  Number of patients in remission for 3 months (primary outcome): 35% T versus 14% R; 
p<0.001† 50% T versus 37% R; p<0.029‡
  Mean (95% CI) time until remission (months): 10.4 (9.1 to 11.7) T versus 14.3 (12.6 to 16.1) 
R; p<0.001
  Duration (months) of all periods of remission: 11.6 (10.1–13.1) T versus 9.1 (7.6–10.6) R; 
p=0.025
  ACR50: 58% T versus 43% R; p<0.01† 46% T versus 45% R; p=NS‡ Functional outcome at 
1 year† and at 2 years‡
  HAQ mean±SD-change: −0.44±0.59 T versus −0.39±0.66 R; p=NS†; −0.41±0.64 T 
versus −0.42±0.76 R; p=NS‡ Radiographic outcome at 2 years
  Annual radiographic progression: median (IQR) change (units/year): 0 (0–2.0) T versus 0 
(0–2.5) R; p=0.9
Routine control 
group (R)
Decrease of SJC, if 
number of SJ unchanged, 
assessors’ judgement, 
looking at TJC, ESR, PGA
3 Months 148
(C) Fransen et al28
Targeted group (T) DAS28<3.2 LDA 1 Month starting, 
then 2 months, 
then 3 months 
(both groups)
205 Clinical outcome at 24 weeks
  Patients in DAS28/LDA: 31% T versus 16% R; p=0.028
  Mean±SD changes in DAS28: −0.4±1.0 T versus −0.14±1.2 R; p=0.36
  DMARD changes: 20% T versus 9% R; p=0.013 Functional data: NR (NS) Radiographic: NR
Routine control 
group (R)
Opinion of treating 
rheumatologist
179
(D) Symmons et al29
Targeted group (T) CRP<twice the upper 
limit of normal range 
TJC=0 and SJC=0 
Symptom control
At least every 
4 months (both 
groups)
233 Clinical outcome at 3 years: (adjusted mean difference (95% CI))
  EGA: 3.76 (0.03–7.52); p=0.045
  OSRA: 0.41 (0.01–0.71); p=0.010
  SJC, TJC, ESR and PGA: p=NS Functional outcome at 3 years:
  HAQ (primary outcome): sign deterioration in both arms; mean difference between T and R: 
p=0.82 Radiographic outcome at 3 years:
  Total Larsen score: deterioration in both arms of (signiﬁ  cant in routine group (p=0.035) but 
not in the targeted group (p=0.093); difference T versus R: p=NS
  Eroded joint count: increased slightly in both treatment arms, difference T versus R: p=NS
Routine control 
group (R)
Symptom control 233
(E) Edmonds et al31 (abstract)
Targeted group I CRP normal range 1 Month 
(both groups)
  82 Clinical outcome at 2 years:
  Target ‘SJC<3’ was met in 29%, target ‘normal CRP’ in 41% of visits (p: NA) Functional 
outcomes: NR Radiographic outcomes at 2 years
  Radiographic progression scores NS between study arms but: erosion progression 0.2±1.0 
versus 1.0±2.5 (p<0.03), JSN 0.3±1.3 versus 1.2±2.6 (p<0.03), total score 0.5±1.6 versus 
2.2±4.2 (p<0.005) if AUC-CRP target achieved, as compared to not achieved (not the case for 
SJC-target) (p NA).
Targeted group II SJC <3   85
Routine control 
group
– 8 2
(F) van Tuyl et al30
Targeted group I DAS28<3.2 LDA 8 Weeks, then 
13 weeks (both 
groups)
  11 Clinical outcomes at 40 weeks
  Remission rates: in both targeted arms: 90% (after 8 and 21 weeks: 57% and 76%)
  ACR20/50/70/90: 100%/95%/71%/43% Functional outcomes: NR Radiographic outcomes: NR
Targeted group II Cartilage degradation: 
CTX-II excretion 
≤150 nmol/mmol creatinine
 10
(G) Stenger et al32
Targeted group (T) CRP decrease >50% 8 Weeks (both 
groups)
139 Clinical outcomes at 1 year† and at 2 years‡
  AUC-CRP (mg (week/l; median (range)): 1136 (144–3563) T versus 1836 (26–8051) R; 
p=0.02†; 1963 (212–8515) T versus 3025 (46–15632) R; p=0.002‡ Functional outcomes: NR 
Radiographic outcomes at 1 year† and at 2 years‡
  Median (range) progression rate: 17.0 (0–74) T versus 17.5 (0–130) R; p=0.22† 26.0 
(0–100) T versus 35 (1–188) R; p=0.03‡
Routine control 
group (R)
Opinion of treating 
rheumatologist
 89
*OR (95% CI); †outcome at 1 year; ‡outcome at 2 years.
AUC, area under the curve; ACR, American College of Rheumatology; CAMERA, Computer Assisted Management in Early Rheumatoid Arthritis; CRP, C reactive protein; CTX-II, 
C-terminal cross-linking of type II collagen; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drugs; EGA, evaluator global assessment; ESR, erythrocyte 
sedimentation rate; EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; JSN, joint space narrowing; LDA, low disease activity; NR, not reported; 
OSRA, overall status in rheumatoid arthritis; PGA, physician’s global assessment; SJC, swollen joint count; TICORA, tight control of rheumatoid arthritis; TJC, total joint count; TSS, 
total Sharp score.
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the reported radiographic progression favoured the intensive 
  treatment (table 1).
Additional studies
A number of studies used the treat to target concept, but, in 
contrast to the mentioned papers, did not have a non-targeted 
control arm, since all arms pursued the same target with dif-
ferent treatment sequences (supplementary table S4). Likewise, 
several trials compared step-up with combination regimes, dose 
titration of agents or different therapies to reach a deﬁ  ned target 
without directly addressing the efﬁ  cacy of treating to target. A 
description of these studies can be found in the supplementary 
material accompanying this manuscript.
DISCUSSION
Our review revealed that only few controlled studies investi-
gated the value of strategic treatment schedules. Importantly, 
study designs and evaluated targets were very heterogeneous; 
for example, the Edmonds and van Tuyl studies are inher-
ently different in design as compared to the others in that their 
approach compares two T2T approaches while the others com-
pare a T2T approach with the routine approach. Nevertheless, 
all studies investigating early disease showed signiﬁ  cantly better 
clinical outcomes of the targeted approach. Functional outcomes, 
reported in two trials, failed to show signiﬁ  cant gains.27 29 Four 
studies compared radiographic outcomes,26 27 29 32 of which two 
showed a signiﬁ  cant beneﬁ  t of the targeted therapy.26
Five26–28 30 32 studies investigated early disease (using different 
deﬁ  nitions of ‘early’ – see supplementary table S3). Only one 
trial29 focused explicitly on late disease (duration: >5 years) and 
found no advantage of tight control on functional outcomes. 
Thus, patients with established RA seem to be underinvesti-
gated regarding the value of treating to a target. Since longer dis-
ease duration impairs treatment outcomes,33 extending results 
from early RA to the general patient population could be mis-
leading. Furthermore, just focusing on HAQ might also be mis-
guiding, since with increasing disease duration responsiveness 
of physical function to therapeutic interventions decreases (even 
to placebo levels).34
Utilised targets showed considerable heterogeneity (table 1, 
ﬁ   gure 2). Among the randomised trials comparing targeted 
versus routine approaches, three out of four employed state 
targets,26 28 29 an approach that has been favoured as being 
more appropriate than assessing changes from baseline.35 
Only in CAMERA,27 the target was formulated as reaching 
deﬁ  ned improvement criteria. Also, visit intervals were notice-
ably heterogenous: clinical assessments were performed from 
  monthly26–28 31 to every 429 36 months. Two trials randomised 
patients to different visit intervals.26 37 In both, patients assigned 
to intensive strategy were seen monthly, those in routine care 
every 3 months.
In conclusion, only few studies have used a randomised 
approach to test the value of treatment to a speciﬁ  c target. 
However, all of them provided compelling evidence of clin-
ical beneﬁ  ts of such an approach. However, more data are 
needed concerning radiographic and functional outcomes 
and patients with longstanding RA have not been sufﬁ  ciently 
investigated.
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